4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001209191-21-037475
Chief Financial Officer sold 15,037 shares at an average $21.64 ($325,383)
- Chief Financial Officer acquired 33,189 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ruffo Frank Chief Financial Officer | 2021-06-01 | Option exercise | +33,189 | 184,909 | D: show line 1 in the form | ||
| Ruffo Frank Chief Financial Officer | 2021-06-02 | Sale | −12,587 | $21.51 | $270,748 | 172,322 | D: show line 2 in the form |
| Ruffo Frank Chief Financial Officer | 2021-06-02 | Sale | −2,450 | $22.30 | $54,635 | 169,872 | D: show line 3 in the form |
| Open-market sales · 15,037 sh · avg $21.64 · $325,383 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Ruffo Frank Chief Financial Officer | 2021-06-01 | Option exercise · Restricted Stock Units | −33,189 | 0 | D: show line 4 in the form |
Loading xslF345X03/doc4.xml…